Study of MEDI-522 Administered by Subcutaneous Injection to Adults With Plaque Psoriasis
NCT00192517
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
44
Enrollment
INDUSTRY
Sponsor class
Conditions
Psoriasis
Interventions
DRUG:
MEDI-522
OTHER:
Placebo
Sponsor
MedImmune LLC